(Fighting against New Coronary Pneumonia) National Medical Insurance Administration: New coronary pneumonia treatment drugs can be included in the proposed new scope of the 2020 drug catalog
China News Service, Beijing, August 18th. One year later, China's National Medical Insurance Catalogue was adjusted again. The National Medical Security Administration of China recently issued a document stating that the scope of new drugs that can be included in the 2020 drug catalogue includes: drugs for the treatment of respiratory diseases related to new coronary pneumonia, drugs included in the "National Essential Drug List (2018 Edition)", etc.
According to the "Order No. 1" of the National Medical Insurance Administration at the end of July-the "Interim Measures for the Administration of Medications for Basic Medical Insurance", China has established and improved the dynamic adjustment mechanism of the medical insurance catalog, which is adjusted once a year in principle. The interim measures will come into effect on September 1, 2020.
The recently released "Work Plan for the Adjustment of the 2020 National Medical Insurance Drug List" clarified that the scope of new drugs that can be included in the 2020 drug list include: drugs for the treatment of respiratory diseases related to new coronary pneumonia; included in the National Essential Drug List (2018 Edition) )"; drugs that are included in the list of urgently needed overseas new drugs for clinical use, the list of encouraged generic drugs, or the list of children's drugs that are encouraged to research and develop, and have been approved for marketing by the State Drug Administration before August 17, 2020 (inclusive, the same below); The two batches of nationally organized drugs are selected for centralized procurement; from January 1, 2015 to August 17, 2020, new generic drugs approved for marketing by the national drug regulatory authority.
Since the outbreak of the new crown pneumonia, the National Medical Insurance Bureau has issued a "two guarantees" policy, which implements first treatment and settlement after all confirmed and suspected patients. As of July 19, 135,500 medical insurance settlements occurred in the country for confirmed and suspected patients with new coronary pneumonia, involving medical expenses of 1.847 billion yuan (RMB, the same below), medical insurance payments of 1.232 billion yuan, and the payment ratio reached 67%.
Experts pointed out that the adjustment of the medical insurance catalog plans to include the new coronary pneumonia-related therapeutic drugs into the new scope, which will provide important support for the normalization of the prevention and control of the new coronary pneumonia epidemic.
The National Medical Security Administration stated that it will announce the results of the adjustment of the drug catalog from November to December 2020. (Finish)